TP53 and myelodysplastic syndrome: This information should be included in the clinical report [45], since bi-allelic TP53 inactivation predicts the risk of death and leukemic transformation independently of the IPSS-R in MDS, and has also been associated with resistance to lenalidomide in del(5q) patients [46,47].